ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C5H9NO2
CAS番号:
分子量:
115.13
EC Number:
205-702-2
UNSPSC Code:
12352209
NACRES:
NA.26
Beilstein/REAXYS Number:
80810
MDL number:
InChI key
ONIBWKKTOPOVIA-BYPYZUCNSA-N
InChI
1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
SMILES string
OC(=O)[C@@H]1CCCN1
biological source
non-animal source
assay
≥98.5%
form
crystalline powder
technique(s)
cell culture | mammalian: suitable
impurities
endotoxin, heavy metals, residual solvents, tested
mp
228 °C (dec.) (lit.)
solubility
H2O: 50 mg/mL
application(s)
pharmaceutical (small molecule)
foreign activity
cytotoxicity, tested
Quality Level
類似した製品をお探しですか? 訪問 製品比較ガイド
General description
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
M-Clarity Program
Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
To request documentation for this product, please contact Customer Support and select ‘Product Documentation′. Please note that access to the documentation for this product requires a confidentiality disclosure agreement.
Application
L-Proline is a non-essential amino acid. Peptides bond to Proline, making it a useful building block for proteins. It can be used as a cell culture media component for the commercial biomanufacture of therapeutic recombinant proteins and monoclonal antibodies.
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
P8865-25KG: + P8865-BULK: + P8865-1KG: + P8865-100G: + P8865-10KG: + P8865-VAR:
jan
Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
R A Wevers et al.
Clinical chemistry, 40(7 Pt 1), 1245-1250 (1994-07-01)
Although spin-echo techniques are often used to obtain 1H-NMR spectra of serum or plasma samples, they do not provide reliable quantitative analyses of metabolites. We present a standardized procedure, optimized for sensitivity, for using single-pulse 1H-NMR spectroscopy to analyze deproteinized
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
Salvatore Petta et al.
Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)